Iterum Therapeutics plc (ITRM)
NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
As of 10:11AM EDT. Market open.
| Previous close | 1.5500 |
| Open | 1.5700 |
| Bid | 1.5600 x 100 |
| Ask | 1.6900 x 100 |
| Day's range | 1.5700 - 1.6100 |
| 52-week range | 0.6220 - 2.5000 |
| Volume | |
| Avg. volume | 180,472 |
| Market cap | 26.653M |
| Beta (5Y monthly) | 2.36 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Insider Monkey
Iterum Therapeutics plc (NASDAQ:ITRM) Q4 2023 Earnings Call Transcript
Iterum Therapeutics plc (NASDAQ:ITRM) Q4 2023 Earnings Call Transcript March 28, 2024 Iterum Therapeutics plc beats earnings expectations. Reported EPS is $-0.94, expectations were $-1.02. ITRM isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Hello, everyone, and welcome to the […]
- Thomson Reuters StreetEvents
Q4 2023 Iterum Therapeutics PLC Earnings Call
Q4 2023 Iterum Therapeutics PLC Earnings Call
- Zacks
Iterum (ITRM) Plans Early Submission of UTI Drug NDA, Stock Up
Iterum (ITRM) stock rises as the company gears up to submit a regulatory application to the FDA seeking approval for oral sulopenem to treat adult women with uUTIs ahead of schedule.
© 2024 Yahoo. All rights reserved.